Genomic Valley Biotech

Genomic Valley Biotech Equity

Delisted·Sep 16, 2026

The The Equity of Genomic Valley Biotech (539206.BO) as of Oct 16, 2026 is 38.98 M INR. In the previous year, The Equity was 35.42 M INR — a change of 10.05% (higher).

Equity

38.98 MINR

YoY

10.05%

Last updated:

In 2025, Genomic Valley Biotech's equity was 38.98 M INR, a 10.05% increase from the 35.42 M INR equity in the previous year.

The Genomic Valley Biotech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2022
28.79 M INR
Jan 1, 2023
35.27 M INR
Jan 1, 2024
35.42 M INR
Jan 1, 2025
38.98 M INR
The Genomic Valley Biotech Equity history
YEAREquityYoY
38.98 MINR+10.05%
35.42 MINR+0.43%
35.27 MINR+22.52%
28.79 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomic Valley Biotech Stock analysis

What does Genomic Valley Biotech do? Genomic Valley Biotech Ltd, identified by the ticker symbol 539206.BO and the ISIN code INE574D01010, is an Indian corporate entity established within the biotechnology and life sciences sector. The company maintains its primary operational headquarters in Bahadurgarh, a city located in the state of Haryana, India. This geographical positioning places the firm within a significant industrial and technological hub in northern India, facilitating its business operations and strategic partnerships within the regional ecosystem. The organization entered the public equity markets through an Initial Public Offering that was officially executed on July 10, 2015. This milestone marked a critical transition in the company's corporate history, allowing it to raise capital from public investors and increase its visibility within the financial markets. The listing on the Bombay Stock Exchange under the specified ticker provides a mechanism for public trading and valuation of the company's shares. While specific details regarding its industry classification and sector categorization are not explicitly defined in the available reference data, the company's name and operational focus imply a specialization in genomic technologies and biotechnological solutions. The corporate profile is further accessible through its official digital presence at http://www.genomicvalley.com/, where stakeholders and interested parties can obtain additional information regarding its business activities, corporate governance, and financial performance. As a publicly traded entity, Genomic Valley Biotech Ltd is subject to the regulatory frameworks and disclosure requirements mandated by Indian securities regulators. The company's journey from its foundational establishment to its public listing in 2015 represents a structured growth trajectory aimed at expanding its reach and capabilities in the competitive biotech landscape. Investors and analysts monitoring the Indian market may track the company's performance through its stock ticker, utilizing the ISIN for precise identification in global financial databases. The lack of explicit sector or industry tags in the provided data does not diminish the company's operational identity, which remains anchored in the scientific and technological advancements associated with genomics and biotechnology. The headquarters in Bahadurgarh serves as the central node for administrative, research, and strategic decision-making processes, supporting the company's ongoing initiatives and market engagements. Genomic Valley Biotech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Genomic Valley Biotech's Equity

Genomic Valley Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Genomic Valley Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Genomic Valley Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Genomic Valley Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Genomic Valley Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Genomic Valley Biotech stock

The Equity of Genomic Valley Biotech is 38.98 M INR in 2025.

The Equity of Genomic Valley Biotech changed from 35.42 M INR to 38.98 M INR, representing a 10.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Genomic Valley Biotech since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Genomic Valley Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genomic Valley Biotech

All Key Metrics — Genomic Valley Biotech